Latest news with #Evolysse
Globe and Mail
22-07-2025
- Business
- Globe and Mail
Evolus to Report Second Quarter Financial Results on August 5, 2025
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13754888. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc.
Globe and Mail
11-07-2025
- Business
- Globe and Mail
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of July 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed on each vesting date. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook.
Time Business News
13-06-2025
- Health
- Time Business News
Evolysse Smart Hydration Redefined with Advanced HA Fusion Technology
In the ever-evolving world of skincare, hydration remains a cornerstone of healthy, radiant skin. However, traditional moisturizers often fall short in delivering deep, long-lasting hydration. Enter Evolysse Smart Hydration, a revolutionary skincare innovation powered by Advanced HA Fusion Technology. With increasing environmental stressors, pollution, and lifestyle factors impacting skin health, What is Evolysse demand for intelligent hydration solutions has never been higher. Evolysse combines science and nature to create a breakthrough formula that hydrates and enhances the skin's natural barrier, ensuring lasting moisture retention and a youthful glow. Skin hydration is more than just applying water or a basic moisturizer. The skin's outermost layer, the stratum corneum, relies on a delicate balance of water and lipids to maintain elasticity, suppleness, and protection. When this balance is disrupted, skin becomes dry, flaky, and prone to premature aging. Hyaluronic Acid (HA) is a naturally occurring molecule in the skin known for its exceptional water-retention capabilities. A single gram of HA can hold up to 1,000 times its weight in water, making it a hydration powerhouse. However, not all HA is created equal. Traditional HA molecules vary in size, affecting their penetration and efficacy. Most skincare products use standard HA, which: Only provides surface-level hydration Evaporates quickly without locking in moisture Fails to address deeper skin layers This is where Evolysse's Advanced HA Fusion Technology comes into play. What is Evolysse proprietary Advanced HA Fusion Technology is a multi-dimensional approach to hydration, combining: Multi-Molecular Weight HA – A blend of high, medium, and low-weight HA molecules ensures hydration penetrates every layer of the skin. High-weight HA forms a protective moisture barrier on the surface. Medium-weight HA hydrates the mid-layers for plumpness. Low-weight HA penetrates deeply to stimulate collagen and long-term hydration. Smart Delivery System – Encapsulated HA ensures controlled release, providing 24-hour hydration without the need for reapplication. Bio-Fermented HA – Sustainably sourced and bio-fermented for higher purity and enhanced skin compatibility. Feature Traditional HA Products Evolysse Smart Hydration Hydration Depth Surface-level only Multi-layered (deep, mid, surface) Duration Short-term (few hours) Long-lasting (24-hour release) Technology Standard HA Advanced HA Fusion + Smart Delivery Skin Benefits Temporary plumping Enhanced barrier, collagen support This intelligent system ensures that skin remains hydrated, resilient, and youthful throughout the day. Unlike traditional moisturizers that simply coat the skin's surface, Evolysse provides deep, continuous hydration at the cellular level, helping to prevent transepidermal water loss (TEWL). Evolysse strengthens the skin's natural lipid barrier, offering protection against environmental stressors such as pollution and UV exposure. Well-hydrated skin appears plumper, reducing the visibility of fine lines. The low-weight HA in Evolysse also stimulates collagen production for long-term anti-aging benefits. With consistent use, skin becomes more elastic and resilient, combating sagging and dullness. Whether you have dry, oily, combination, or sensitive skin, Evolysse's pH-balanced, non-comedogenic formula ensures optimal hydration without irritation. Traditional skincare takes a passive approach—adding moisture only when dryness is noticeable. In contrast, smart hydration, like that in Evolysse, is proactive, responding to the skin's needs in real time for continuous, adaptive care. The future of skincare lies in personalized hydration. Imagine a system where: Smart sensors detect skin's hydration levels AI adjusts HA delivery based on environmental conditions Custom-blended serums are created for individual needs Evolysse is at the forefront of this movement, paving the way for next-gen skincare innovations. Formulated with bio-fermented HA and housed in eco-conscious packaging, Evolysse supports the global move toward green beauty—delivering high performance without compromising the planet. Start with a gentle cleanser to remove impurities. Dispense 2-3 drops onto fingertips. Gently press onto face and neck. Allow absorption before layering other products. For maximum benefits, follow with a moisturizer or sunscreen. Morning & Night for optimal hydration. Under Makeup for a smooth, plump base. Evolysse Smart Hydration isn't just another skincare product—it represents a new era in skin wellness. Powered by Advanced HA Fusion Technology, it offers smarter, deeper, and longer-lasting hydration than conventional approaches. TIME BUSINESS NEWS
Yahoo
13-05-2025
- Business
- Yahoo
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls' thesis on EOLS. Evolus, Inc. (EOLS)'s share was trading at $11.76 as of May 7th. EOLS's forward P/E was 117.65 according to Yahoo Finance. ATeam/ Evolus has quickly positioned itself as a disruptive force in the global injectable aesthetics market, traditionally dominated by pharmaceutical giants like AbbVie and Galderma. The company's flagship product, Jeuveau, has gained significant traction, capturing 13% of the U.S. neuromodulator market within just five years. Jeuveau's success can be attributed to its innovative go-to-market strategy, which combines pharmaceutical credibility with direct-to-consumer (DTC) marketing techniques typically associated with the beauty industry. By offering Jeuveau at a price point approximately 20% below Botox, it has been able to resonate with a younger demographic, particularly those between the ages of 20 and 40. This pricing strategy, combined with a robust presence in over 16,000 medical practices—including a growing number of medical spas that lack strong brand loyalty—has made Jeuveau a popular alternative to Botox. This market acceptance has positioned Evolus favorably in the expanding U.S. injectables market, which is undergoing structural changes driven by greater societal acceptance, a wider demographic appeal, and an aging population with increasing disposable income. The broader U.S. injectables market is seeing strong growth, with the popularity of non-invasive cosmetic procedures accelerating. The U.S. is expected to follow more mature markets like Korea, where injectables are already deeply embedded in cosmetic routines. This trend represents a significant growth opportunity for Evolus, which is now at a crucial inflection point in its business development. The company plans to diversify beyond neuromodulators with the upcoming launch of Evolysse, a premium line of dermal fillers developed in partnership with Symatese, the same formulation partner behind Galderma's Restylane. Evolus is seeking FDA approval for several aesthetic indications, including lip and cheek enhancement. This expansion into dermal fillers is expected to contribute approximately $200 million to Evolus' revenue over time, further strengthening its position in the injectables space. Moreover, Evolus is adopting an innovative subscription-based model, 'Club Evolus,' which offers customers quarterly treatments for a monthly fee. This model is designed to drive customer loyalty and predictable revenue streams, providing a clear path to sustained growth. With these initiatives in play, Evolus is targeting annual revenue growth of 25-27%, with projections aiming for $700 million in revenue by 2028, up from an estimated $266 million in 2024. If the company achieves these goals, it expects to reach positive cash flow by 2026. However, despite its promising growth trajectory, Evolus remains a high-risk, high-reward investment. Several factors introduce uncertainty, including regulatory dependencies around product approvals and manufacturing partnerships. Additionally, since all Evolus procedures are out-of-pocket and not covered by insurance, the company's performance is sensitive to broader consumer spending trends. Economic downturns could impact discretionary spending on cosmetic procedures, presenting a potential headwind to growth. Still, if Evolus can continue executing its strategy effectively, maintain rational competition, and convert growth into sustainable profits, the company could deliver significant upside to investors. Furthermore, Evolus' ability to capture market share in the growing injectable aesthetics sector—through innovation, branding, and consumer loyalty—positions it as a compelling investment despite the inherent risks. Evolus stands out among its competitors, particularly Galderma, which, although boasting successful injectable brands like Dysport and Restylane, has a more diluted business model. Galderma also operates legacy divisions, including skincare products like Cetaphil, which is losing ground to competitors like L'Oréal's Cerave, and a dermatological drug pipeline that limits its growth potential. In contrast, Evolus offers a cleaner, more focused investment thesis, solely concentrating on injectable aesthetics. While it is still smaller and must prove long-term profitability, the simplicity of Evolus' business model and its focus on high-growth injectables makes it a more attractive pure-play investment in the sector. Valuing Evolus is complex due to the limited number of direct competitors, but looking at mature self-pay therapeutic companies like Align, Sonova, and Alcon—whose valuations range from 13-17x EV/EBITDA—can provide some context. If Evolus reaches $700 million in revenue by 2028 and delivers an 11% EBITDA margin, which is lower than its 20% long-term target but adjusted for stock-based compensation, the company would generate approximately $77 million in EBITDA. Using a 15x EV/EBITDA multiple, this could result in annualized returns of around 20%, contingent on continued growth. However, key risks remain. Evolus relies on licensing agreements for its neuromodulator Jeuveau from Daewoong and its fillers from Symatese, both of which come with volume requirements and finite durations. Any disruptions to these agreements could create a going concern issue for the company. Moreover, competition from South Korean entrants and a fragmented filler market pose additional risks. As competition intensifies, pricing pressures could erode margins, further complicating Evolus' growth strategy. Another risk comes from tariffs. New U.S. import duties on products from South Korea and France could impact Jeuveau and Evolysse fillers, though they may be exempt as pharmaceuticals. If tariffs do apply, Evolus may need to raise prices by 5-6% to offset the cost increases, which could be manageable given the strong margins and pricing power of its products. Competitors like AbbVie and Galderma may also face similar tariff-related challenges, potentially leveling the playing field. Despite these risks, Evolus benefits from a seasoned management team, including executives with deep experience from Allergan, such as CEO David Moatazedi and CMO Rui Avelar. This leadership, combined with a focused business model and significant upside potential, makes Evolus a standout investment in the injectable aesthetics space. While the company must prove its long-term profitability, its focused approach and market opportunities position it for potential substantial growth in a rapidly expanding industry. Evolus, Inc. (EOLS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held EOLS at the end of the fourth quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of EOLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than EOLS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
13-05-2025
- Business
- Yahoo
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls' thesis on EOLS. Evolus, Inc. (EOLS)'s share was trading at $11.76 as of May 7th. EOLS's forward P/E was 117.65 according to Yahoo Finance. ATeam/ Evolus has quickly positioned itself as a disruptive force in the global injectable aesthetics market, traditionally dominated by pharmaceutical giants like AbbVie and Galderma. The company's flagship product, Jeuveau, has gained significant traction, capturing 13% of the U.S. neuromodulator market within just five years. Jeuveau's success can be attributed to its innovative go-to-market strategy, which combines pharmaceutical credibility with direct-to-consumer (DTC) marketing techniques typically associated with the beauty industry. By offering Jeuveau at a price point approximately 20% below Botox, it has been able to resonate with a younger demographic, particularly those between the ages of 20 and 40. This pricing strategy, combined with a robust presence in over 16,000 medical practices—including a growing number of medical spas that lack strong brand loyalty—has made Jeuveau a popular alternative to Botox. This market acceptance has positioned Evolus favorably in the expanding U.S. injectables market, which is undergoing structural changes driven by greater societal acceptance, a wider demographic appeal, and an aging population with increasing disposable income. The broader U.S. injectables market is seeing strong growth, with the popularity of non-invasive cosmetic procedures accelerating. The U.S. is expected to follow more mature markets like Korea, where injectables are already deeply embedded in cosmetic routines. This trend represents a significant growth opportunity for Evolus, which is now at a crucial inflection point in its business development. The company plans to diversify beyond neuromodulators with the upcoming launch of Evolysse, a premium line of dermal fillers developed in partnership with Symatese, the same formulation partner behind Galderma's Restylane. Evolus is seeking FDA approval for several aesthetic indications, including lip and cheek enhancement. This expansion into dermal fillers is expected to contribute approximately $200 million to Evolus' revenue over time, further strengthening its position in the injectables space. Moreover, Evolus is adopting an innovative subscription-based model, 'Club Evolus,' which offers customers quarterly treatments for a monthly fee. This model is designed to drive customer loyalty and predictable revenue streams, providing a clear path to sustained growth. With these initiatives in play, Evolus is targeting annual revenue growth of 25-27%, with projections aiming for $700 million in revenue by 2028, up from an estimated $266 million in 2024. If the company achieves these goals, it expects to reach positive cash flow by 2026. However, despite its promising growth trajectory, Evolus remains a high-risk, high-reward investment. Several factors introduce uncertainty, including regulatory dependencies around product approvals and manufacturing partnerships. Additionally, since all Evolus procedures are out-of-pocket and not covered by insurance, the company's performance is sensitive to broader consumer spending trends. Economic downturns could impact discretionary spending on cosmetic procedures, presenting a potential headwind to growth. Still, if Evolus can continue executing its strategy effectively, maintain rational competition, and convert growth into sustainable profits, the company could deliver significant upside to investors. Furthermore, Evolus' ability to capture market share in the growing injectable aesthetics sector—through innovation, branding, and consumer loyalty—positions it as a compelling investment despite the inherent risks. Evolus stands out among its competitors, particularly Galderma, which, although boasting successful injectable brands like Dysport and Restylane, has a more diluted business model. Galderma also operates legacy divisions, including skincare products like Cetaphil, which is losing ground to competitors like L'Oréal's Cerave, and a dermatological drug pipeline that limits its growth potential. In contrast, Evolus offers a cleaner, more focused investment thesis, solely concentrating on injectable aesthetics. While it is still smaller and must prove long-term profitability, the simplicity of Evolus' business model and its focus on high-growth injectables makes it a more attractive pure-play investment in the sector. Valuing Evolus is complex due to the limited number of direct competitors, but looking at mature self-pay therapeutic companies like Align, Sonova, and Alcon—whose valuations range from 13-17x EV/EBITDA—can provide some context. If Evolus reaches $700 million in revenue by 2028 and delivers an 11% EBITDA margin, which is lower than its 20% long-term target but adjusted for stock-based compensation, the company would generate approximately $77 million in EBITDA. Using a 15x EV/EBITDA multiple, this could result in annualized returns of around 20%, contingent on continued growth. However, key risks remain. Evolus relies on licensing agreements for its neuromodulator Jeuveau from Daewoong and its fillers from Symatese, both of which come with volume requirements and finite durations. Any disruptions to these agreements could create a going concern issue for the company. Moreover, competition from South Korean entrants and a fragmented filler market pose additional risks. As competition intensifies, pricing pressures could erode margins, further complicating Evolus' growth strategy. Another risk comes from tariffs. New U.S. import duties on products from South Korea and France could impact Jeuveau and Evolysse fillers, though they may be exempt as pharmaceuticals. If tariffs do apply, Evolus may need to raise prices by 5-6% to offset the cost increases, which could be manageable given the strong margins and pricing power of its products. Competitors like AbbVie and Galderma may also face similar tariff-related challenges, potentially leveling the playing field. Despite these risks, Evolus benefits from a seasoned management team, including executives with deep experience from Allergan, such as CEO David Moatazedi and CMO Rui Avelar. This leadership, combined with a focused business model and significant upside potential, makes Evolus a standout investment in the injectable aesthetics space. While the company must prove its long-term profitability, its focused approach and market opportunities position it for potential substantial growth in a rapidly expanding industry. Evolus, Inc. (EOLS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held EOLS at the end of the fourth quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of EOLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than EOLS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
